FOLH1 and posterior cortical atrophy: In vivo targeting of FOLH1 by conjugating auristatin (a cytotoxic agent) to J591 increased the therapeutic index of auristatin by 700‐fold, and improved the median survival of PCa xenografts by 9 months.35